AR122863A1 - Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos - Google Patents
Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismosInfo
- Publication number
- AR122863A1 AR122863A1 ARP210101857A ARP210101857A AR122863A1 AR 122863 A1 AR122863 A1 AR 122863A1 AR P210101857 A ARP210101857 A AR P210101857A AR P210101857 A ARP210101857 A AR P210101857A AR 122863 A1 AR122863 A1 AR 122863A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptides
- modified
- including modified
- agonize
- wild
- Prior art date
Links
- 108010002350 Interleukin-2 Proteins 0.000 title abstract 6
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000000588 Interleukin-2 Human genes 0.000 abstract 5
- 102000010789 Interleukin-2 Receptors Human genes 0.000 abstract 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Biomedical Technology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063047681P | 2020-07-02 | 2020-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122863A1 true AR122863A1 (es) | 2022-10-12 |
Family
ID=77127075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101857A AR122863A1 (es) | 2020-07-02 | 2021-07-01 | Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230235005A1 (https=) |
| EP (1) | EP4175979A2 (https=) |
| JP (1) | JP2023532904A (https=) |
| KR (1) | KR20230035076A (https=) |
| CN (1) | CN116615440A (https=) |
| AR (1) | AR122863A1 (https=) |
| AU (1) | AU2021299552A1 (https=) |
| CA (1) | CA3184618A1 (https=) |
| IL (1) | IL299542A (https=) |
| MX (1) | MX2022016532A (https=) |
| TW (1) | TW202216745A (https=) |
| WO (1) | WO2022006380A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230112632A (ko) | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
| IL308609A (en) | 2021-05-19 | 2024-01-01 | Asher Biotherapeutics Inc | IL-21 polypeptides and target constructs |
| WO2023133393A1 (en) * | 2022-01-05 | 2023-07-13 | Inhibrx, Inc. | Gamma delta t-cell-targeted modified il-2 polypeptides and uses thereof |
| WO2023151661A1 (zh) * | 2022-02-11 | 2023-08-17 | 江苏恒瑞医药股份有限公司 | 免疫缀合物及其用途 |
| CN119546343A (zh) * | 2022-04-27 | 2025-02-28 | 亚设生物治疗公司 | 细胞因子融合蛋白与cd8抗原结合分子的组合 |
| US20240076343A1 (en) | 2022-06-16 | 2024-03-07 | Cephalon Llc | Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof |
| WO2024008126A1 (en) * | 2022-07-06 | 2024-01-11 | Elpiscience (Suzhou) Biopharma, Ltd. | Il2 muteins and uses thereof |
| CN116041539B (zh) * | 2022-10-31 | 2023-07-21 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
| KR20250143339A (ko) * | 2023-02-06 | 2025-10-01 | 메르크 파텐트 게엠베하 | VHH-기반 NKp46 결합제 |
| AU2024330564A1 (en) | 2023-08-30 | 2026-04-02 | Xilio Development, Inc. | Vhh masked cytokines and methods of use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2541651C (en) | 2003-10-22 | 2011-05-24 | Keck Graduate Institute | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
| US20060234205A1 (en) * | 2004-03-05 | 2006-10-19 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
| EP1740615B1 (en) | 2004-03-31 | 2014-11-05 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| WO2015164815A1 (en) * | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| JP7422480B2 (ja) * | 2016-05-04 | 2024-01-26 | アムジエン・インコーポレーテツド | 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 |
| ES2973548T3 (es) * | 2016-12-22 | 2024-06-20 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso |
| KR20250156190A (ko) * | 2018-06-22 | 2025-10-31 | 큐진 인크. | 인터루킨-2 변이체 및 이의 사용 방법 |
| US11492384B2 (en) * | 2018-09-17 | 2022-11-08 | Gi Innovation, Inc. | Fusion protein comprising IL-2 protein and CD80 protein, and use thereof |
| SG11202106700WA (en) * | 2019-01-07 | 2021-07-29 | Inhibrx Inc | Polypeptides comprising modified il-2 polypeptides and uses thereof |
| EP3980051A4 (en) * | 2019-06-05 | 2023-09-13 | Asher Biotherapeutics, Inc. | FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS |
-
2021
- 2021-07-01 US US18/002,613 patent/US20230235005A1/en active Pending
- 2021-07-01 JP JP2022580769A patent/JP2023532904A/ja active Pending
- 2021-07-01 KR KR1020237003798A patent/KR20230035076A/ko active Pending
- 2021-07-01 CA CA3184618A patent/CA3184618A1/en active Pending
- 2021-07-01 EP EP21748720.6A patent/EP4175979A2/en active Pending
- 2021-07-01 IL IL299542A patent/IL299542A/en unknown
- 2021-07-01 TW TW110124255A patent/TW202216745A/zh unknown
- 2021-07-01 MX MX2022016532A patent/MX2022016532A/es unknown
- 2021-07-01 AR ARP210101857A patent/AR122863A1/es unknown
- 2021-07-01 AU AU2021299552A patent/AU2021299552A1/en active Pending
- 2021-07-01 WO PCT/US2021/040061 patent/WO2022006380A2/en not_active Ceased
- 2021-07-01 CN CN202180053315.0A patent/CN116615440A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022006380A2 (en) | 2022-01-06 |
| EP4175979A2 (en) | 2023-05-10 |
| TW202216745A (zh) | 2022-05-01 |
| WO2022006380A3 (en) | 2022-02-24 |
| KR20230035076A (ko) | 2023-03-10 |
| CN116615440A (zh) | 2023-08-18 |
| MX2022016532A (es) | 2023-04-12 |
| CA3184618A1 (en) | 2022-01-06 |
| AU2021299552A1 (en) | 2023-02-02 |
| US20230235005A1 (en) | 2023-07-27 |
| JP2023532904A (ja) | 2023-08-01 |
| IL299542A (en) | 2023-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001779A1 (es) | Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos | |
| AR122863A1 (es) | Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos | |
| CO2019009354A2 (es) | Immunoconjugados de un anticuerpo anti-pd-1 con un mutante il-2 o con il-15 | |
| CL2024003234A1 (es) | Polipéptidos modificados y usos de los mismos. | |
| CO2019003809A2 (es) | Anticuerpos contra proteína alfa reguladora de señal y métodos de uso | |
| MX2023013883A (es) | Polipeptidos multimericos moduladores de linfocitos t y metodos para su uso. | |
| CL2020002477A1 (es) | Proteínas de fusión interleucina-2/receptor alfa de interleucina-2 y métodos de uso | |
| PE20220231A1 (es) | Proteinas de fusion flt3l-fc y metodos de uso | |
| AR114445A1 (es) | Conjugados de il-15, y sus usos | |
| MX2021008144A (es) | Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso. | |
| PE20170503A1 (es) | Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso | |
| CO2018002450A2 (es) | Proteínas de fusión de gitrl y usos de las mismas | |
| AR112048A1 (es) | Anticuerpos cd47 y métodos de uso de los mismos | |
| UY37456A (es) | Inmunoglobulinas y sus usos | |
| MX2019011869A (es) | Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso. | |
| AR107078A1 (es) | Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso | |
| MX2018005063A (es) | Polipéptidos condicionalmente activos. | |
| MX2018009524A (es) | Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso. | |
| MX394735B (es) | Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos. | |
| CO2024004910A2 (es) | Proteína mutante de interleucina-2 y fusión de la misma | |
| MX2020002977A (es) | Agonistas de receptor de peptido similar al glucagon tipo 1 y usos de los mismos. | |
| CU20210041A7 (es) | Péptidos inmunogénicos con motivos de oxidorreductasa | |
| CO2021010786A2 (es) | Toxinas apxia, apxiia y apxiiia inactivadas | |
| MX2021000322A (es) | Enzimas de variante fosfopentomutasa modificada geneticamente. | |
| MX2022006670A (es) | Region fc de anticuerpo teniendo mayor afinidad de union al fcyriib. |